Literature DB >> 23786578

Medical records-based postmarketing safety evaluation of rare events with uncertain status.

Hongyuan Cao1, Lisa M LaVange, Joseph F Heyse, T Christopher Mast, Michael R Kosorok.   

Abstract

We develop a simple statistic for comparing rates of rare adverse events between treatment groups in postmarketing safety studies where the events have uncertain status. In this setting, the statistic is asymptotically equivalent to the logrank statistic, but the limiting distribution has Poisson and binomial components instead of being Gaussian. We develop two new procedures for computing critical values: a Gaussian approximation and a parametric bootstrap. Both numerical and asymptotic properties of the procedures are studied. The test procedures are demonstrated on a postmarketing safety study of the RotaTeq vaccine. This vaccine was developed to reduce the incidence of severe diarrhea in infants.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23786578      PMCID: PMC4491986          DOI: 10.1080/10543406.2013.789886

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  7 in total

1.  Adjusting survival analysis for the presence of unadjudicated study events.

Authors:  T D Cook
Journal:  Control Clin Trials       Date:  2000-06

2.  Meta-analysis and epidemiologic studies in drug development and postmarketing surveillance.

Authors:  R Temple
Journal:  JAMA       Date:  1999-03-03       Impact factor: 56.272

3.  The role of meta-analysis in the regulatory process for foods, drugs, and devices.

Authors:  J A Berlin; G A Colditz
Journal:  JAMA       Date:  1999-03-03       Impact factor: 56.272

4.  Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine.

Authors:  Timo Vesikari; David O Matson; Penelope Dennehy; Pierre Van Damme; Mathuram Santosham; Zoe Rodriguez; Michael J Dallas; Joseph F Heyse; Michelle G Goveia; Steven B Black; Henry R Shinefield; Celia D C Christie; Samuli Ylitalo; Robbin F Itzler; Michele L Coia; Matthew T Onorato; Ben A Adeyi; Gary S Marshall; Leif Gothefors; Dirk Campens; Aino Karvonen; James P Watt; Katherine L O'Brien; Mark J DiNubile; H Fred Clark; John W Boslego; Paul A Offit; Penny M Heaton
Journal:  N Engl J Med       Date:  2006-01-05       Impact factor: 91.245

5.  On the Asymptotic Distribution of the Sum of a Random Number of Random Variables.

Authors:  H Robbins
Journal:  Proc Natl Acad Sci U S A       Date:  1948-04       Impact factor: 11.205

6.  Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems.

Authors:  D A Kessler
Journal:  JAMA       Date:  1993-06-02       Impact factor: 56.272

7.  Safety monitoring of drugs receiving pediatric marketing exclusivity.

Authors:  P Brian Smith; Daniel K Benjamin; M Dianne Murphy; Rosemary Johann-Liang; Solomon Iyasu; Barbara Gould; Robert M Califf; Jennifer S Li; William Rodriguez
Journal:  Pediatrics       Date:  2008-09       Impact factor: 7.124

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.